Accueil   Diary - News   All news Merck and genOway Form CRISPR/Cas9 Strategic Alliance to Develop Rodent Models

Merck and genOway Form CRISPR/Cas9 Strategic Alliance to Develop Rodent Models

 

 

 

  • genOway to acquire exclusive rights to Merck’s foundational genome-editing patents to produce, sell rodent models

 

  • New technologies and solutions to be developed using CRISPR/Cas9 to accelerate delivery of better drugs to patients

 

Darmstadt, Germany, December 10, 2018 – Merck, a leading science and technology company and leader in genome editing, today announced a strategic alliance in the CRISPR/Cas9 rodent model market with France-based biotechnology company genOway.

 

Read the press release